Alexion Pharmaceuticals, Inc. (ALXN)

[stocktrader001]

Alexion Pharmaceuticals, Inc. (ALXN) is reiterated as a “Buy” rating by Collins Stewart

Equities research analysts at Collins Stewart Reiterate a “Buy” rating for shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note released to investors today (Wednesday).



Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) are trading down -1.28% as of Feb 22, 4:00PM EST, hitting 95.50. Alexion Pharmaceuticals, Inc. has a 52 week low of 45.18 and a 52 week high of 95.50. The companies last released earnings were 1.04 per share. were The company has a market cap of 8.53B and a price-to-earnings ratio of 89.54.

http://www.favstocks.com/alexion-pharmaceuticals-inc-alxn-is-reiterated-as-a-buy-rating-by-collins-stewart/2334269/